Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Conditions:   Stomach Cancer;   Stomach Neoplasm;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Ramucirumab;   Drug: Ramucirumab + Paclitaxel
Sponsors:   Federation Francophone de Cancerologie Digestive;   Eli Lilly and Company
Recruiting

https://ift.tt/2BR5l6Z